Kernal Biologics has been awarded $48 million from ARPA-H to develop in vivo CAR T-cell therapies for hematological cancers. This funding is part of ARPA-H’s EMBODY program, aimed at enhancing immune cell engineering.
Amount Raised
$48 Million
Round Type
Funding Round
CambridgeBiotechnologyHealthcareHealth CareresearchInvestors
Description
Kernal Biologics, Inc. has secured up to $48 million in funding from ARPA-H to advance its in vivo mRNA-encoded CAR T-cell program, KR-402. This initiative targets multiple sclerosis and various B-cell malignancies. Collaboration with Stanford University School of Medicine and others will support the project's development
Who to call at Kernal Biologics, and when
A new round usually means Kernal Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kernal Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kernal Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kernal Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kernal Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Kernal Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.